Sean Nolan

Sean Nolan

Independent DirectoratTaysha Gene Therapies· In proxies 2022–2025

Pay in FY2022Taysha Gene Therapies stock -80.6% the same year

Sean Nolan was paid $1.9M in FY2022 (Dec). Taysha Gene Therapies stock fell 80.6% that year.

Pay$100 in the stock at the end of FY21 → $19
Pay is from the Summary Compensation Table of each Taysha Gene Therapies proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. VentasPublic company · 3 yr
    • Independent Director2023 – Present · 3 yrNo stock prices for these years
  2. Taysha Gene TherapiesPublic company · 4 yr
    • Chief Executive Officer and Director2022 – Present · 4 yrStock in role -67%
  3. Chairman of the Board (NASDAQ: TSHA)Public company · 6 yr
    • Director2020 – Present · 6 yrNo stock prices for these years
  4. Taysha Gene Therapies, Inc.Public company
    • Director? – PresentNo stock prices for these years
  5. Public Company DirectorshipsPublic company
    • Director? – PresentNo stock prices for these years
  6. Social Capital Suvretta Holdings CorpPublic company
    • Director? – PresentNo stock prices for these years
  7. IIPublic company · 2 yr
    • Director2021 – 2023 · 2 yrNo stock prices for these years
  8. Neurogene, Inc.Public company · 1 yr
    • Director2019 – 2020 · 1 yrNo stock prices for these years
  9. Neoleukin Therapeutics, Inc.Public company · 5 yr
    • Director2015 – 2020 · 5 yrNo stock prices for these years
  10. Aquinox Pharmaceuticals, Inc.Public company · 4 yr
    • Director2015 – 2019 · 4 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?